Document is current
Any future updates will be listed below
-
Authors
van den Bulk, Jitske
Verdegaal, Els M. E.
Ruano, Dina
Ijsselsteijn, Marieke E.
Visser, Marten
van der Breggen, Ruud
Duhen, Thomas
van der Ploeg, Manon
de Vries, Natasja L.
Oosting, Jan
Peeters, Koen C. M. J.
Weinberg, Andrew D.
Farina-Sarasqueta, Arantza
van der Burg, Sjoerd H.
de Miranda, Noel F. C. C. http://orcid.org/0000-0001-6122-1024
-
Funding
Funding for this research was provided by:
KWF Bas Mulder Award UL (2015-7664)
ZonMw Veni grant (016.176.l44)
Fight Colorectal Cancer-Michael’s Mission-AACR Fellowship in Young Onset, Late-Stage Colorectal Cancer Research 2015 (15-40-1645-DEMI)
LUMC PhD fellowship (-)
- License Information
-
More Information
Article History
Received: 22 July 2019
Accepted: 20 November 2019
First Online: 30 December 2019
Ethics approval and consent to participate
: This study was approved by the Medical Ethical Committee of the Leiden University Medical Centre (protocol P15.282), and all patients provided informed consent. The current research as conformed to the principles of the Declaration of Helsinki and tissue samples were handled according to the medical ethical guidelines described in the Code of Conduct for Proper Secondary Use of Human Tissue of the Dutch Federation of Biomedical Scientific Societies.
: Not applicable.
: T. Duhen and A.D. Weinberg disclose that they have submitted a patent regarding therapeutic and diagnostic use of the CD39<sup>+</sup>CD103<sup>+</sup> CD8<sup>+</sup> T cells in cancer patients. The other authors declare that they have no competing interests.
